Adeona Pharmaceuticals and National Neurovision Research Institute (NNRI) Collaborate to Test Flupirtine for Retinitis Pigmentosa

Published: Dec 02, 2008

ANN ARBOR, MI and OWINGS MILLS, MD--(Marketwire - December 02, 2008) - National Neurovision Research Institute (NNRI), a research support organization for the Foundation Fighting Blindness, the leading non-government funding source for inherited orphan retinal degeneration research and Adeona Pharmaceuticals, Inc. (AMEX: AEN) announced today a research collaboration whereby NNRI will fully fund preclinical studies to evaluate the potential of flupirtine for the treatment of retinitis pigmentosa (RP), a blinding eye disease that currently lacks an FDA approved treatment.

Back to news